The Valley Desk

ArticleCrohn's & colitis 360Published

Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Lewis Katz School of Medicine, Temple University. Affiliation source

Publication record

Type
Article
Venue
Crohn's & colitis 360
Published
Subject terms
Fatigue; Ulcerative colitis; Urgency; Mirikizumab; Modified Mayo Score
PubMed ID
40260308
PubMed Central ID
PMC12010086
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal